Table 3 Favourable neurological prognosis according to natremia and to osmolality in each of the four trials
3a. Crude analysis of favourable neurological prognosis according to natremia category and trial | |||||
|---|---|---|---|---|---|
Favourable neurological prognosis on day 180, n (%) | All (n = 417/1135) | HYPERION (n = 46/560) | TTM24/48* (n = 221/345) | COMACARE (n = 78/120) | XENON (n = 72/110) |
Normonatremia | 363/893 (40.7) | 40/408 (9.8) | 198/295 (67.1) | 63/95 (66.3) | 62/95 (65.3) |
Hyponatremia | 50/211 (23.7) | 3/125 (2.4) | 22/46 (47.8) | 15/25 (60.0) | 10/15 (66.7) |
Hypernatremia | 4/31 (12.9) | 3/27 (11.1) | 1/4 (25.0) | 0/0 (0.0) | 0/0 (0.0) |
3b. Crude analysis of favourable neurological prognosis according to osmolality category and trial | |||||
|---|---|---|---|---|---|
Favourable neurological prognosis on day 180, n (%) | All (n = 188/730) | HYPERION (n = 42/507) | TTM24/48* (n = –) | COMACARE (n = 74/114) | XENON (n = 72/109) |
Normo-osmolality | 151/490 (30.8) | 24/299 (8.1) | – | 62/96 (64.6) | 65/95 (68.4) |
Hypo-osmolality | 12/80 (15.0) | 3/65 (4.6) | – | 6/9 (66.7) | 3/6 (50.0) |
Hyperosmolality | 25/160 (15.6) | 15/143 (10.5) | – | 6/9 (66.7) | 4/8 (50.0) |